Compound-7p

Compound 7P (CAS 1890208-58-8) is a synthetic sulfonamidoacetamide with the systematic name 2-[(2-methoxyphenyl)[(4-methylphenyl)sulfonyl]amino]-N-(4-methoxy-3-pyridinyl)acetamide and molecular formula C22H23N3O5S (molecular weight 441.50 g/mol). The compound was identified at Hanyang University (Republic of Korea) through a phenotypic cell-based screening campaign of chemical libraries followed by iterative structure-activity-guided optimization, culminating in its characterization as the lead compound in a 2016 Journal of Medicinal Chemistry report by Ku, Park, Lee, and colleagues [1]. Compound 7P promotes neurite outgrowth in cultured primary neurons derived from the hippocampus, cerebral cortex, and retina, and in an in vivo rat model of optic nerve crush injury it induces the growth of GAP-43-positive regenerating axons at distances extending beyond 1500 micrometers distal to the crush epicenter, a finding that demonstrates translation of the in vitro neurite outgrowth phenotype into bona fide central nervous system axon regeneration.

The compound was selected as the optimization lead on the basis of three convergent improvements over the parent hit (compound 1): enhanced neurite outgrowth activity in the primary neuron phenotypic assay, improved aqueous solubility attributable to the introduction of a 4-methoxypyridinyl amide pharmacophore replacing a lipophilic aniline, and markedly improved metabolic stability (61.2 percent of parent compound remaining after microsomal incubation, compared to 0.7 percent for the original hit) driven by reduction of the calculated partition coefficient from 3.76 to 2.43 [1]. These properties rendered compound 7P suitable for the in vivo optic nerve injury study that constitutes the principal translational evidence for the compound class.

The molecular target or targets through which compound 7P stimulates axon regeneration have not been definitively identified. The phenotypic screening approach that generated the compound was target-agnostic, and the published literature does not report a defined receptor, enzyme, or signaling node as the primary binding partner. Contextual evidence from the broader axon regeneration field implicates pathways including the mammalian target of rapamycin (mTOR), the signal transducer and activator of transcription 3 (STAT3), and phosphatase and tensin homolog (PTEN) signaling as determinants of central nervous system axon growth competence, but the specific engagement of these pathways by compound 7P has not been demonstrated in pathway-deconvolution or target-identification studies.

Compound 7P has no clinical development history. No human pharmacokinetic, safety, or efficacy data have been generated. The compound is not approved by any regulatory authority for any indication. It has entered the research-chemical supply chain as a nootropic-marketed powder on the basis of the published preclinical neurite outgrowth and axon regeneration data, but no clinical evidence supports cognitive enhancement, neuroprotection, or any other therapeutic claim in humans. This monograph documents the chemistry, structure-activity optimization, published preclinical pharmacology, the limited mechanistic and pharmacokinetic characterization, sourcing and handling considerations, and a comparative assessment against five alternative axon-regeneration-promoting small molecules on five competency standards. Investigators should treat compound 7P as an early-stage preclinical research tool with a single peer-reviewed primary publication and no human translational data.